Pfizer Inc. Announces Final Results of Exchange Offers
02 October 2015 - 10:30PM
Business Wire
Pfizer Inc. (“Pfizer”) (NYSE: PFE) announced today the final
results of its previously announced offers to exchange any and all
validly tendered and accepted notes of each series listed in the
table below (collectively, the “Hospira Notes”) issued by Hospira,
Inc., a recently acquired subsidiary of Pfizer, for new notes to be
issued by Pfizer (collectively, the “Pfizer Notes”), and the
related solicitations of consents to amend the indenture governing
the Hospira Notes and the Hospira Notes (together, the “Exchange
Offers”). A Registration Statement on Form S-4 (File No.
333-206758) (the “Registration Statement”) relating to the issuance
of the Pfizer Notes was filed with the Securities and Exchange
Commission (“SEC”) on September 3, 2015, was amended by Amendment
No. 1 to the Registration Statement filed with the SEC on September
16, 2015, and was declared effective by the SEC on September 25,
2015.
As of 11:59 p.m., New York City time, on October 1, 2015 (the
“Expiration Date”), the aggregate principal amounts listed in the
table below of each series of Hospira Notes had been validly
tendered and not validly withdrawn pursuant to the terms and
conditions of the Exchange Offers. The final settlement of the
Exchange Offers is expected to take place on or about October 5,
2015.
CUSIP No.
Series of
Hospira
Notes
to be
Exchanged
Aggregate
Principal
Amount
Outstanding
Tenders and
Consents
Received as
of the
Expiration
Date
Percentage
of Total
Outstanding
Principal
Amount of
such Series
of Hospira
Notes
441060AJ9
6.05%
Notes due
2017
$550,000,000 $502,779,000 91.41% 441060AM2
5.20%
Notes due
2020
$350,000,000 $329,916,000 94.26% 441060AN0
5.80%
Notes due
2023
$350,000,000 $342,017,000 97.72% 441060AL4
5.60%
Notes due
2040
$500,000,000 $494,769,000 98.95%
The Exchange Offers were made pursuant to the terms and
conditions set forth in Pfizer’s prospectus, dated as of September
25, 2015 (the “Prospectus”), which forms a part of the Registration
Statement, and the related Amended and Restated Letter of
Transmittal and Consent (the “Letter of Transmittal”) that contain
the complete description of the terms and conditions of the
Exchange Offers.
The dealer managers for the Exchange Offers were:
Citigroup Global Markets Inc.
390 Greenwich Street, 1st Floor
New York, New York 10013
Attention: Liability Management Group
(800) 558-3745 (toll free)
(212) 723-6106 (collect)
Goldman, Sachs & Co.
200 West Street
New York, New York 10282
Attention: Liability Management Group
(800) 828-3182 (toll free)
(212) 902-5183 (collect)
The exchange agent and information agent for the Exchange Offers
is:
Global Bondholder Services Corporation65 Broadway – Suite
404New York, New York 10006Attn: Corporate ActionsBank and Brokers
Call Collect: (212) 430-3774All Others, Call Toll Free: (866)
470-3900
The proposals set forth in this message are subject to
compliance with all local legal and regulatory obligations,
including the obligation to inform and or consult with labor
organizations, works councils, trade unions and employee
representatives.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151002005334/en/
Pfizer Inc.Media:Joan Campion, 212-733-2798201-761-9384
(M)Joan.Campion@pfizer.comorInvestor:Ryan Crowe,
212-733-8160215-260-0914 (M)Ryan.Crowe@pfizer.com
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2024 to May 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From May 2023 to May 2024